Search clinical trials for: Tislelizumab

Total 437 results

Zhejiang Cancer Hospital

Recruiting

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

Colorectal Cancer Metastatic | Microsatellite Stable | Mismatch Repair-proficient

China
Jazz Pharmaceuticals
BeiGene, Ltd.

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric Neoplasms

Korea, Republic of, Belgium, Netherlands, Spain, Japan, China, Germany, United Kingdom, Malaysia, Taiwan, Portugal, France, Italy, Australia, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Singapore, Poland and more
Peking University Cancer Hospital & Institute

Recruiting

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Melanoma

China
Hebei Medical University Fourth Hospital

Recruiting

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Tongji Hospital
Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Qilu... and other collaborators

Not yet recruiting

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (BRIGHT)

Ovarian Cancer

China
Haibo Zhang

Recruiting

Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC

Small Cell Lung Cancer (SCLC)

China
First Affiliated Hospital of Zhejiang University

Recruiting

Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma (TACT)

Neoadjuvant Therapy | Immunotherapy | Lung Squamous Cell Carcinoma

China
Ruijin Hospital

Not yet recruiting

Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma (TiTanec)

Cervical Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Fudan University

Recruiting

ALPPS Combined With Tislelizumab in Liver Malignancy

Liver Malignant Tumors

China
Sun Yat-sen University

Not yet recruiting

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Locally Advanced Rectal Cancer

China
Peter MacCallum Cancer Centre, Australia

Recruiting

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

Cancer

Australia
Zhejiang University
Shandong Cancer Hospital and Institute; First Hospital of China Medical University and other collaborators

Recruiting

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma | Adjuvant Therapy

China
Fudan University

Recruiting

GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Biliary Tract Carcinoma

China
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaborators

Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC (iCROSS)

Esophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage III

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma (TAXE-GC)

Gastric Cancer

China
Fudan University

Recruiting

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Metastatic Colorectal Cancer

China
Quanli Gao

Not yet recruiting

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Malignant Melanoma
RenJi Hospital
BeiGene; Huidu Shanghai Medical Sciences Ltd

Recruiting

Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (TACBIN-01)

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Antineoplastic Agents | Tislelizumab Antineoplastic Agents, Immunological

China
Fudan University

Recruiting

Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma (RETICULA-NPC)

Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Unresectable Nasopharyngeal Carcinoma | Stereotactic Body Radiation Therapy (SBRT)

China
Fudan University

Not yet recruiting

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study (TEMPLATE)

Triple Negative Breast Cancer

China
Sichuan Provincial People's Hospital

Recruiting

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (NeoATCT)

Triple-negative Breast Cancer

China
Beijing Friendship Hospital
Xuanwu Hospital, Beijing; Beijing Chao Yang Hospital; Tianjin Medical University... and other collaborators

Recruiting

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Colorectal Neoplasms

China
Ruijin Hospital

Not yet recruiting

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma

China
Changhai Hospital

Recruiting

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Recurrent Pancreatic Cancer

China
Peking Union Medical College Hospital
Henan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaborators

Recruiting

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Peking University
Peking University Cancer Hospital & Institute

Not yet recruiting

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

NK/T Cell Lymphoma

China
Wuhan Union Hospital, China

Recruiting

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

China
Sun Yat-sen University

Recruiting

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Hodgkin Lymphoma | Chemotherapy Effect

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
University of Cologne

Not yet recruiting

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)

Classical Hodgkin Lymphoma

Germany
Sun Yat-sen University

Recruiting

Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Stomach Cancer

China
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Shanghai Ninth People's Hospital Affiliated to...

Not yet recruiting

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

Head and Neck Cancer | Radiation | PD-1
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
Ruijin Hospital

Not yet recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Shanghai Zhongshan Hospital

Recruiting

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

Advanced Gastric Cancer

China
Huiqiang Huang

Recruiting

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Ruijin Hospital

Recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Fudan University

Recruiting

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Cholangiocarcinoma, Intrahepatic

China
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
BeiGene

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Japan, United States, France, Mexico, Germany, Argentina, Brazil, Korea, Republic of, Turkey
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Non-Muscle Invasive Bladder Urothelial Carcinoma | High-Risk

China
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma | EBV-Positive DLBCL, Nos

China
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, Colorectal

United States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands

Search clinical trials for: Tislelizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations